Date: 2026-01-15Category: Not ApplicableState: Union GovernmentCountry: Europe
Decision of the EEA Joint Committee No 196/2025 of 19 September 2025 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2026/3]
**Executive Summary**
The Decision of the EEA Joint Committee No 196/2025, adopted on September 19, 2025, amends Annex II to the EEA Agreement. The amendment incorporates several Commission Implementing Regulations related to active substances, and enters into force on September 20, 2025.
**Key Points / Main Content**
* **Amendment of Annex II, Chapter XV:**
* Several Commission Implementing Regulations are added to points within Chapter XV of Annex II to the EEA Agreement, specifically regarding regulations (EU) No 540/2011 and (EU) 2015/408.
* **Incorporated Regulations:**
* **Regulation (EU) 2025/808:** Deletes gamma-cyhalothrin, ipconazole, and oxamyl from the list of active substances for candidate substitution.
* **Regulation (EU) 2025/833:** Renews approval of the active substance lenacil.
* **Regulation (EU) 2025/845:** Approves elemental iron as a low-risk active substance.
* **Authentic Texts:**
* The texts of Implementing Regulations (EU) 2025/808, (EU) 2025/833, and (EU) 2025/845 in Icelandic and Norwegian languages shall be authentic and published in the EEA Supplement to the Official Journal of the European Union.
* **Entry into Force:**
* This Decision enters into force on September 20, 2025, provided all notifications under Article 103(1) of the EEA Agreement have been made.
* **Publication:**
* This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
**Impact Analysis**
**EEA Joint Committee**
* **Impact:** Responsible for adopting and implementing the decision, ensuring compliance with the EEA Agreement.
* **Action Required:** Publish the decision in the Official Journal and ensure the amendment is properly integrated into Annex II of the EEA Agreement.
**European Parliament and Council**
* **Impact:** Their regulations regarding active substances are incorporated into the EEA Agreement.
* **Action Required:** Continue monitoring and updating regulations related to active substances to ensure ongoing compliance and relevance.
**EEA Member States (Iceland, Norway)**
* **Impact:** Their national regulations and practices related to technical regulations, standards, testing, and certification need to align with the amended Annex II.
* **Action Required:** Review and update national legislation and procedures to reflect the incorporated Commission Implementing Regulations, ensuring compliance with the updated EEA Agreement.
**Stakeholders in Agriculture and Related Industries**
* **Impact:** Active substances used in agriculture will have revised status (deletion, renewal, or approval), impacting their availability and use.
* **Action Required:** Adapt practices to comply with the new regulations regarding active substances.
Key Entities Referenced
Annex II to the EEA Agreement: Technical regulations, standards, testing and certification annex of the EEA Agreement
Commission Implementing Regulation (EU) No 540/2011: Commission Implementing Regulation (EU) No 540/2011
Commission Implementing Regulation (EU) 2015/408: Commission Implementing Regulation (EU) 2015/408
Regulation (EC) No 1107/2009: Regulation (EC) No 1107/2009 of the European Parliament and of the Council
EEA Agreement: Agreement on the European Economic Area
Official Journal EN
of the European Union L series
2026/3 15.1.2026
DECISION OF THE EEA JOINT COMMITTEENo 196/2025
of 19 September 2025
amending Annex II (Technical regulations, standards, testing and certification) to the
EEA Agreement [2026/3]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98
thereof,
Whereas:
(1) Commission Implementing Regulation (EU) 2025/808 of 5 May 2025 amending Implementing Regulation
(EU) 2015/408 as regards the deletion of gamma-cyhalothrin, ipconazole and oxamyl from the list of active
substances to be considered as candidates for substitution(1)is to be incorporated into the EEA Agreement.
(2) Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 renewing the approval of the active substance
lenacil in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and
amending Commission Implementing Regulations (EU) No 540/2011 and (EU) 2015/408(2) is to be incorporated
into the EEA Agreement.
(3) Commission Implementing Regulation (EU) 2025/845 of 5 May 2025 approving the active substance elemental iron
as a low-risk active substance in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of
the Council, and amending Commission Implementing Regulation (EU) No 540/2011(3)is to be incorporated into
the EEA Agreement.
(4) Annex II to the EEA Agreement should therefore be amended accordingly,
HAS ADOPTED THIS DECISION:
Article 1
Chapter XV of Annex II to the EEA Agreement is amended as follows:
1. The following indents are added in point 13a (Commission Implementing Regulation (EU) No 540/2011):
‘— 32025 R 0833: Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 (OJ L, 2025/833,
6.5.2025),
— 32025 R 0845: Commission Implementing Regulation (EU) 2025/845 of 5 May 2025 (OJ L, 2025/845,
6.5.2025).’
2. The following indents are added in point 13zzzzt (Commission Implementing Regulation (EU) 2015/408):
‘— 32025 R 0808: Commission Implementing Regulation (EU) 2025/808 of 5 May 2025 (OJ L, 2025/808,
6.5.2025),
— 32025 R 0833: Commission Implementing Regulation (EU) 2025/833 of 5 May 2025 (OJ L, 2025/833,
6.5.2025).’
(1) OJ L, 2025/808, 6.5.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/808/oj.
(2) OJ L, 2025/833, 6.5.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/833/oj.
(3) OJ L, 2025/845, 6.5.2025, ELI: http://data.europa.eu/eli/reg_impl/2025/845/oj.
ELI: http://data.europa.eu/eli/dec/2026/3/oj 1/2EN
OJ L, 15.1.2026
3. The following points are inserted after point 13zzzzzzzzzzzzzzzh (Commission Implementing Regulation
(EU) 2025/150):
‘13zzzzzzzzzzzzzzzi. 32025 R 0833: Commission Implementing Regulation (EU) 2025/833 of 5 May 2025
renewing the approval of the active substance lenacil in accordance with Regulation (EC)
No 1107/2009 of the European Parliament and of the Council, and amending Commission
Implementing Regulations (EU) No 540/2011 and (EU) 2015/408 (OJ L, 2025/833,
6.5.2025).
13zzzzzzzzzzzzzzzj. 32025 R 0845: Commission Implementing Regulation (EU) 2025/845 of 5 May 2025
approving the active substance elemental iron as a low-risk active substance in accordance
with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and
amending Commission Implementing Regulation (EU) No 540/2011 (OJ L, 2025/845,
6.5.2025).’
Article 2
The texts of Implementing Regulations (EU) 2025/808, (EU) 2025/833 and (EU) 2025/845 in the Icelandic and Norwegian
languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 20 September 2025, provided that all the notifications under Article 103(1) of the
EEA Agreement have been made(*).
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European
Union.
Done at Brussels, 19 September 2025.
For the EEA Joint Committee
The President
Stefán Haukur JÓHANNESSON
(*) No constitutional requirements indicated.
2/2 ELI: http://data.europa.eu/eli/dec/2026/3/oj